In this context and encouragingly, the effectiveness of the combination of ACT with IL-21-primed polyclonal cytolytic T cells and anti-CTLA-4 antibody in a melanoma patient that had failed prior treatments with ACT and anti-CTLA-4 has recently been reported [69]. The gene discussed is IL21; the disease is melanoma.